- Filter by
- Categories
- Tags
- Show all
- Article
- Confusion
- Contract
- Copyright
- Corporate
- Domain Names
- Employment
- Expungement
- Expungement
- Grey Marketing
- Industrial Designs
- Licensing
- Obviousness
- Opposition
- Passing Off
- Patent
- Patent Infringement
- Patent Strategy
- PCK News
- PM(NOC)
- Procedure
- Prosecution
- Services
- Summary
- Trade Secrets
- Trademark
- Use
- Validity
- Abandonment
- Abstract Theorems
- Abuse of Process
- Accounting of Profits
- Alice/Mayo Test
- Ambiguity
- Anticipation
- Appeal
- Apple
- Artificial Intelligence
- Assignment
- Bargain Theory
- Biosimilar
- Biotech Patents
- Branding
- business
- CAFC
- Canada
- Certificate of Supplementary Protection
- Chemical Patent
- CIPO
- claim
- Claim Construction
- Class Actions
- College of Patent Agents and Trademark Agents
- combination drugs
- Commercial Success
- Common General Knowledge
- Confidential Information
- Confusion
- Contract
- Copyright
- Copyright Infringement
- Costs
- Counterfeit
- Court of Appeals for the Federal Circuit
- COVID-19
- Damages
- Data Protection
- Design Patents
- Distinctiveness
- Diversity
- DNA Patents
- Domain Names
- Dosage Range
- Double Patenting
- Due Care
- E-Commerce
- Enablement
- Estoppel
- Evidence
- Expert Evidence
- Fair Use
- Federal Court
- Federal Court of Appeal
- File Wrapper Estoppel
- Food and Drug Regulations
- Fraud
- funding
- Generic Drugs
- Hague Agreement
- Indefiniteness
- Induced Infringement
- Industrial Designs
- Injunction
- Innovation
- Innovative Drugs
- Insufficient Disclosure
- Intellectual Property
- Inter Partes Review
- Investors
- IP Litigation
- IP Strategy
- IP Treaty
- IPIC
- Jurisdiction
- Law Firm
- Licensing IP
- Madrid Protocol
- Methods of Medical Treatment
- Non-Infringing Alternative
- Non-Practicing Entity
- Novelty
- Obviousness
- Official Marks
- On-Sale Bar
- Overbreadth
- Ownership & Inventorship
- Passing Off
- Patent Act
- Patent Agent
- Patent Appeal Board
- Patent Application
- Patent Drafting
- Patent Fees
- Patent Infringement
- Patent Law
- Patent Lawyer
- Patent Litigation
- Patent Prosecution
- Patent Rules
- Patent Strategy
- Patent Term Adjustment
- Patent Textbook
- Patent Trolls
- Patent Validity
- Patentable Subject Matter
- Patents
- PCT
- Pharmaceutical Patent
- Pharmaceutical Pricing
- PM(NOC)
- PMPRB
- Prior Art
- Prior Disclosure
- prior use
- Priority
- Privilege
- Product Specificity
- Promise Doctrine
- Provisional Patent
- Punitive Damages
- Reinstatement
- Remedies
- SCOTUS
- Selection Patent
- Software
- Software Copyright
- Software Patent
- Sound Prediction
- Springboard Profits
- SRED
- Standard of Review
- Start-up
- Startups
- Supreme Court of Canada
- Technology
- Trade Secrets
- Trademark
- Trademark Agent
- Trademark Expungement
- Trademark Infringement
- Trademark Law
- Trademark Opposition
- Trademark Registration
- Trademarks Act
- United States
- Use
- USPTO
- Utility
November 6, 2015
November 6, 2015
The USPTO is proposing a 48% increase in government fees to obtain a design patent.
October 7, 2015
October 7, 2015
Gilead Sciences, Inc v Canada (Health), 2015 FC 610 - Gilead's assertion that its patent is valid would be relitigating old issues and an abuse of PM(NOC) proceedings.
October 6, 2015
October 6, 2015
Abb Technology AG, ABB Inc v Hyundai Heavy Industries Co, Ltd, 2015 FCA 181 - The FCA suggested that although claim construction is reviewed on a correctness standard, claim construction is so heavily reliant on expert witnesses that perhaps it should be reviewed on a palpable and overriding error standard.
October 2, 2015
October 2, 2015
Akamai Technologies, Inc, v Limelight Networks, Inc, 09-1372 - The CAFC held that where more than one actor is involved in infringing the steps in a patent, one of the actors can be held liable for the entirety of the infringement if that actor “directs or controls the other’s performance.”
September 30, 2015
September 30, 2015
OrthoArm Incorporated v GAC International, LLC, 2015 ONSC 5097 - The ONSC was to undertake the analysis that would normally be done at a Markman hearing: to perform claim construction on the US patent and apply that construction to determine whether there is infringement.
September 22, 2015
September 22, 2015
Many startups are basing their business plans and valuations on their innovation; patents and industrial designs can be the most valuable asset of the company. One of the best strategies to secure protection for your innovation involves the filing of a self-written provisional patent application. On October 21, beginning at 5 p.m., PCK will be providing a hands-on session in which founders can learn the basics of patents from Andrew Currier.
September 18, 2015
September 18, 2015
ClearCorrect Operating LLC, et al v International Trade Commission (No 2014-1527) - An appeal to the Federal Circuit will determine whether the ITC has jurisdiction over digital patent infringement: the ability to block the importation of patent-infringing “articles” if those articles take the form of digital information.
September 16, 2015
September 16, 2015
Novartis Pharmaceuticals Canada Inc v Teva Canada Limited, 2015 FC 770 - Novartis was able to uphold its patent against allegations of invalidity from Teva, but not without the Federal Court making a number of razor thin distinctions between what the patent promised and what it did not.
September 15, 2015
September 15, 2015
Eli Lilly Canada Inc v Canada (Attorney General), 2015 FCA 166 - The FCA rejected the notion adopted by the Federal Court that a higher level of specificity is required to adhere to the Regulations than is required for an element to be claimed as a matter of claim construction, bringing the law in line with Industry Canada proposed amendments.
September 9, 2015
September 9, 2015
AstraZeneca Canada Inc v Apotex Inc, 2015 FCA 158 - The FCA acknowledged that the word “will” often refers to an expectation or goal rather than a promise, but still held that the FC did not err in finding that a promise was made when reading the patent as a whole from the eyes of a skilled reader.
September 8, 2015
September 8, 2015
ADIR v Apotex Inc, 2015 FC 721 - In an accounting of profits case, the FC stated that if a non-infringing alternative is to be considered, it “cannot be what one would have done had one complied with the law”.
September 2, 2015
September 2, 2015
AstraZeneca Canada Inc v Apotex Inc, 2015 FC 322 - Claim 1 was worded general enough to capture Apotex’s subcoating layer even though Apotex’s subcoating layer was generated by an in situ chemical reaction, a process that the patentee had not contemplated.
August 20, 2015
August 20, 2015
USPTO Proposes AIA Rule Changes - Proposes to affirm the "broadest reasonable interpretation standard" in IPR proceedings and other changes.
August 17, 2015
August 17, 2015
Microsoft Corporation v Proxyconn, Inc, - The “broadest reasonable interpretation standard” (“BRI”) standard is the standard for claim construction in Inter Partes Review IPR proceedings and newly substituted claims must be demonstrated to be patentable over the prior art of record.
August 10, 2015
August 10, 2015
Kimble et al v Marvel Entertainment, LLC, 576 U.S. ____ (2015) - The U.S. Supreme Court upheld the 50 year old rule from Brulotte v Thys Co, 379 US 29, that prohibits royalties from being charged on formerly patented products after the patent has expired.
June 30, 2015
June 30, 2015
In the age of the “Lean Startup” $100,000 can be enough to get a startup well off the ground. However, with such tight budgets and limited funding there is often not much room left to pay a professional patent agent several thousand dollars to draft your patent application. This article provides some pointers on how to draft your own provisional software patent application.
June 30, 2015
June 30, 2015
Groves v Canasonics Inc, 2015 ABQB 314 - After a falling out between a director and Canasonics Inc., the former director sought to ensure that any intellectual property in critical unpatented tools remained his own, and sought to reverse the transfer of a number of patents that he had already assigned to the company.
June 27, 2015
June 27, 2015
CD 1377 - Security Point Media's patent on “Advertising Trays for Security Screening” was found to be nonobvious considering a number of factors, such as the impact of the invention on the industry.
May 21, 2015
May 21, 2015
ViiV Healthcare ULC v Teva Canada Limited, 2015 FCA 93 - The FCA confirmed that paragraph 4(2)(a) of the Patented Medicines (Notice of Compliance Regulations) requires that a patent listed on the register requires an “exacting threshold of specificity” between what is claimed in the patent and what has been approved in the Notice of Compliance. However, proposed amendments to the PM(NOC) Regulations would reverse this holding.
May 20, 2015
May 20, 2015
The proposed amendments would dispose of the product specificity requirement that was interpreted by the Federal Court of Appeal in paragraphs 4(2)(a) and 4(2)(b) of the PM(NOC) Regulations.